In the uremic status of end-stage renal disease (ESRD), the lysine residue of erythropoietin (EPO) is carbamylated and decreases in activity, resulting in the production of non-functional EPO, which leads to hypoxemia [273,274]. The gene discussed is EPO; the disease is chronic kidney disease.